Patisiran was applied for treatment of TTR mediated amyloidosis which could reduce the expression of target protein mutated transthyretin (TTR) to 80% at the dose of 0.3 mg/kg every 3 weeks (Ole et al., 2015). This evidence concerns the gene TTR and amyloidosis.